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Abstract
C-type natriuretic peptide (CNP) is one of the three most important members of the human 
natriuretic peptide family, sharing with them a highly conserved 17-aminoacid ring structure, essential to 
elicit its biological actions by binding to its specific receptor NPR-B. CNP acts in a paracrine or autocrine 
way and it is cleared from plasma circulation by the NPR-C receptor. This is one of the reasons why its 
plasma levels are usually low. CNP is widely spread in human tissues, being localized in a variety of cells 
such as cardiac and vascular smooth muscle cells, chondrocytes, macrophages, glial cells, and renal, 
brain and reproductive tissues. In the cardiovascular system, CNP is stored in endothelial cells and 
exert different actions like vasodilation in large conduction vessels, and anti-proliferative, pro-apoptotic, 
anti-fibrotic and anti-hypertrophic properties in cardiomyocytes; it also inhibits neointimal restenosis 
and reduces cardiac ischemia-reperfusion injury and vascular constrictive remodeling. In addition, it 
has been suggested that CNP acts as an endothelium derived hyperpolarizing factor as a consequence 
of its hyperpolarizing action in resistance arterial smooth vessels muscle. Regarding its clinical aspects, 
it has been demonstrated the relation between CNP and different cardiovascular pathologies such 
as heart failure, myocardial infarction, cardiac remodeling, arterial hypertension, angiogenesis and 
revascularization, restenosis, atherosclerosis, pulmonary hypertension, and myocardial aging. 
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Introduction
The endocrine properties of the heart were described for the 
first time by de Bold et al. in 1981, who demonstrated that the right 
atrium produces and secretes a natriuretic and diuretic compound, 
characterized and named three years later as atrial natriuretic peptide 
(ANP) [1]. This was the first member of the natriuretic peptide (NP) 
family to be identified [1,2]. Natriuretic peptides (NPs) are hormones 
produced by the heart in response to myocardium stretching and 
cardiac overload [3]. This family includes atrial or A-type natriuretic 
peptide, brain or B-type natriuretic peptide (BNP), C-type natriuretic 
peptide (CNP), and urodilatin, which is synthesized by the kidney and 
is present in human urine [4]. There are two other NPs apparently not 
produced by humans: DNP, isolated from the venom of Dendroaspis 
angusticeps or eastern green mamba, and TNP, isolated from the 
venom of Oxyuranus microlepidotus, also known as inland or western 
taipan [4]. The aim of this work is to review the latest evidence about 
the clinical role of CNP on the cardiovascular system.
Natriuretic peptides family and receptors
ANP and BNP are important factors synthesized mainly in the 
heart and contribute to the regulation of hydroelectrolytic balance 
and maintenance of vascular smooth muscle tone [5]. These effects 
are exerted directly by these hormones or indirectly through 
antagonism of the renin-angiotensin-aldosterone system [5]. They 
also play a role in adipose tissue generation and lipid metabolism [5-
7]. Like other NPs, CNP is secreted as a pro-hormone and needs to be 
cleaved by proteases to become biologically active [2]. Under normal 
conditions, ANP is usually synthesized by the atrial myocardium 
while BNP is synthesized primarily by the ventricular myocardium 
[2]. On the other hand, CNP is produced by endothelial cells, but it 
is also present at the central nervous system [2,8]. The NPs are able 
to bind to three distinct cell surface receptors, natriuretic peptide 
receptor A (NPR-A), natriuretic peptide receptor B (NPR-B) and 
natriuretic peptide receptor C (NPR-C) [3]. NPR-A and NPR-B are 
transmembrane receptors coupled to particulate guanylate cyclase 
and are responsible in mediate the NPs biological actions, while 
NPR-C is coupled to an inhibitory G protein and is considered a 
clearance receptor through internalization and degradation of NPs 
[9] (Table 1). 
C-Type natriuretic peptide
CNP was the third NP to be identified, and it was first purified 
Table 1: Natriuretic peptides receptors and distribution.
NPR-A NPR-B NPR-C
Binding 
affinity of 
NPs (2,4)
ANP>BNP>>CNP CNP>ANP>BNP ANP>CNP>BNP
Distribution 
(2)
vascular smooth muscle 
cells and endothelial 
cells; adipose, renal, 
adrenal, hepatic and 
brain tissues; heart
chondrocytes, brain, 
lung, heart, ovary 
fibroblasts and 
vascular smooth 
muscle cells
adipose tissue
and kidney
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in 1990 from porcine brain tissue [10]. It is the most spread NP in 
humans, localized in cardiac and vascular smooth muscle cells, 
chondrocytes, macrophages, glial cells, renal and brain tissues, 
and reproductive tissues [6,11,12]. CNP shares a highly conserved 
17-aminoacid disulfide ring structure with other members of 
the natriuretic peptide family but lacks of the carboxy-terminal 
extension present in both ANP and BNP [2]. The ring structure 
sequence is essential for receptor binding and to exert its biological 
activity [13]. Encoded in chromosome 2, CNP gene has two different 
forms, both derived from a pre-pro-hormone with a 126-aminoacid 
structure [11]. The enzymatic cleavage of this molecule generates a 
53-aminoacid compound called CNP-53, and the active biological 
form of 22-aminoacid called CNP-22, primarily found in plasma and 
cerebrospinal fluid [14] (Figure 1).
Transcription of CNP gene is regulated by different factors such 
as several pro-inflammatory cytokines including tumor necrosis 
factor alpha, interleukin-1, transforming growth factor beta, and 
basic fibroblast growth factor [13]. CNP secretion is also stimulated 
by bacterial lipopolysaccharides, shear stress and by ANP and BNP, 
being BNP much more potent than ANP [11,13]. CNP triggers a 
variety of important functions that are not related between them, 
such as regulation of endochondral bone ossification, central nervous 
system functions (in particular brain and pituitary), female and male 
reproductive systems, and cardiovascular function maintenance 
through endothelium and vascular smooth muscle regulation [5]. 
Although considered a natriuretic peptide, CNP apparently has no 
relevant effects on renal water and sodium excretion [2].
CNP acts in a paracrine or autocrine way, while ANP and BNP act 
by an endocrine mechanism [5]. Consequently, CNP plasma levels are 
usually low (femtomole per milliliter range) and it is rapidly cleared 
out from blood flow (t1/2 ~ 3 minutes), being its expression restricted 
to those organs and tissues that are regulated by CNP [5,10,11]. CNP 
acts by specific binding to its receptor NPR-B, mainly localized in 
different human tissues such as brain, myocardium, endothelium, 
vascular smooth muscle cells and renal tubular cells [14]. The CNP 
clearance depends on its binding to NPR-C receptors [13] (Figure 1).
CNP and the cardiovascular system
CNP is widely expressed along the vascular bed and is highly 
expressed in endothelium where is stored and plays an important 
role by inducing vasorelaxation in large conduction vessels through 
activation of NPR-B receptor subtype [12]. As a vasodilator agent, 
CNP inhibits the release of endothelin stimulated by angiotensin II 
(Ang II) [15]. CNP can also activate NPR-C receptor that leads to 
an hyperpolarizing effect in resistance vascular bed, suggesting that 
CNP acts as an endothelium derived hyperpolarizing factor (EDHF) 
together with other paracrine endothelial vasorelaxant mediators 
such as nitric oxide (NO) and prostacyclin [2,13,16,17].
CNP exhibit several actions on cardiomyocytes such as anti-
proliferative, pro-apoptotic, anti-fibrotic and anti-hypertrophic effects 
[18,19]. It also inhibits neointimal restenosis and reduces cardiac 
ischemia-reperfusion injury and vascular constrictive remodeling 
[18]. These beneficial effects should be related to the inhibition of 
cardiac fibroblasts collagen synthesis due to an inhibitory effect on 
DNA [12,19]. Furthermore, CNP could regulate blood pressure by 
promoting a potent endothelium-independent vasodilatory action in 
small resistant arteries [7]. The expression of CNP in injured arterial 
vessels stimulates inducible nitric oxide synthase secretion leading to 
NO production [14]. It also inhibits angiotensin I vasoconstrictive 
effect but not that of Ang II, suggesting that CNP may exert local 
endogenous regulatory actions on vascular angiotensin converting 
enzyme (ACE) [14,15] (Figure 2).
The abundant location of CNP to endothelial cells and the 
fact that transcription of its gene may be regulated by several 
pro-inflammatory cytokines could explain its important role in 
modulating the activity of immune cells. Kiemer et al. demonstrated 
that CNP suppressed in vitro production of pro-inflammatory cyclo-
oxygenase 2- derived prostaglandin E2 in isolated cells [20]. ANP 
also inhibits vascular inflammation in vivo. It has been reported that 
perivascular application of CNP inhibits neointimal hyperplasia of 
vein grafts in mouse, rabbit, and pig models [21-23].
Figure 1: Generation of CNP (CNP-22) from the pre-pro-CNP and its 
interaction with NPR-B and NPR-C clearance receptor. The binding of CNP-22 
to NPR-B, coupled to a particulate guanylate cyclase, enables the conversion 
of guanosine triphosphate (GTP) to cGMP as the second messenger, which 
mediates the biological effects of CNP-22. The 17-aminoacid disulfide ring 
structure of the CNP-22 lacks of carboxy-terminal extension.
Figure 2: CNP organs and tissues targets, and its specific effects and actions 
on the cardiovascular system.
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Heart failure
In 1993, using immunohistochemistry techniques, Wei et al. 
found higher CNP tissue concentration in atrial and ventricular 
myocardium of patients undergoing coronary bypass graft surgery 
and from patients with end-stage heart failure undergoing cardiac 
transplantation, compared to hearts from normal donors [24]. 
In 2003, another study demonstrated that CNP plasma levels 
significantly increased in coronary sinus in patients undergoing 
right and left heart catheterization as part of their congestive heart 
failure treatment (coronary sinus: 4.59±1.54 pg/mL versus aortic 
root: 3.55±1.53 pg/mL; p<0.035) [25]. These findings correlated 
directly with CNP myocardial production [25]. Moreover, del Ry et 
al. demonstrated that plasma CNP levels were significantly higher in 
chronic heart failure (CHF) patients compared to healthy subjects 
in relation to clinical severity evaluated according to the New York 
Heart Association (NYHA) [26-28]. In this study, CNP plasma level 
in healthy subjects was 2.7±0.2 pg/ml; in NYHA class I patients it 
was 4.9±0.7 pg/ml; in NYHA class II patients it was 7.0±0.4 pg/ml 
(p<0.001 versus controls); in NYHA class III patients it was 9.6±0.7 pg/
ml (p<0.001 versus controls and class I and II), and in NYHA class IV 
patients it was 11.8±2.0 pg/ml (p<0.001 versus controls, class I and II) 
[26]. These data suggests that elevated CNP from cardiac tissue could 
be related to an increasing myocardial dysfunction [12]. Another 
study reported that CNP is synthesized and secreted by cardiac 
fibroblasts in order to inhibit cardiomyocytes hypertrophy [5]. Taking 
all these considerations together, it seems that the heart produces 
and secretes CNP during heart failure triggering an important 
compensatory physiological response to cardiac remodeling [13]. In 
this setting, the high levels of CNP secretion are apparently related 
to the severity of the disease, as it was showed by the progressive 
increment in CNP plasma levels with worsening of symptoms, as 
well as the negative relationship between plasma CNP levels and left 
ventricular ejection fraction [3,25]. Passino et al demonstrated that 
CNP plasma concentration can be positively affected by a therapeutic 
intervention, such as physical training in heart failure (HF) patients 
[29]. They hypothesized that the decrease in plasma concentrations 
of the hormone observed at the end of a period of aerobic training 
could be due to improvement of the endothelial function achieved 
after an aerobic exercise-training program [29]. On the other hand, 
Zakeri et al. observed that urinary excretion of CNP is elevated in 
acute decompensated heart failure patients [30]. Nevertheless its 
utility as a biomarker for adverse outcomes prediction in HF patients 
is still unknown [30].
Myocardial infarction and cardiac remodeling
Experimental studies performed by Hobbs et al demonstrated 
that both CNP and NPR-C contribute to regulate the coronary blood 
flow in ischemic cardiac tissue and protect the heart against ischemia/
reperfusion (I/R) injury by reducing the size of the infarction zone 
[31]. They also demonstrated that CNP maintains the levels of left 
ventricular developed pressure and coronary perfusion pressure 
as be observed in pre-ischemic situation [31]. In addition, Soeki et 
al. showed that in vivo administration of CNP improved cardiac 
function and that it might reduce cardiac remodeling post myocardial 
infarction (MI) by its anti-hypertrophic and anti-fibrotic effects [32]. 
They observed that CNP considerably reduced the enlargement of 
the left ventricle (LV) after MI with no effects on arterial pressure 
(LV end-diastolic dimension: MI+CNP: 7.7±0.1 mm; MI+vehicle: 
8.3±0.1 mm; sham: 6.7±0.1 mm; p< 0.01) [32]. Moreover, they 
observed a markedly reduction in cardiac fibrosis, demonstrated 
by an important attenuation of the morphometrical collagen 
volume fraction augmentation in the heart regions non-affected by 
MI (MI+CNP: 3.9±0.3%; MI+vehicle: 5.7±0.5%; sham: 3.1±0.2%, 
p<0.01) [32]. They also showed that CNP markedly attenuated the 
increase in cardiomyocytes cross-sectional area [32]. Del Ry et al. 
reported that the increased levels of cardiac CNP after MI could be 
related to an increase in vascularization nearby the infarct zone and 
to the I/R process [33]. The density of the cardiovascular network 
(overall length of capillaries and the number of branch points) was 
markedly higher in the infarct border zone (BZ) compared with the 
non-infarcted remote zone (RZ) and with healthy myocardium (N) 
(BZ: 20.40±1.47; RZ: 17.40±2.80; N: 11.40±0.85; p<0.001 N vs. BZ; 
p=0.04 N vs. RZ) [33]. The vasculogenesis effect could be mediated 
by an increase in CNP levels that triggers a positive stimulation for 
vascular endothelial growth factor secretion [33]. 
These results obtained from experimental models correlates 
with those observed at clinical setting. In humans, endogenous an 
exogenous CNP could act as a protector factor for damage caused 
by ventricular remodeling and I/R after a MI, because of its anti-
hypertrophic effect over cardiomyocytes and its anti-proliferative 
action over cardiac fibroblasts [3,11].
Arterial hypertension
One of the features of arterial hypertension is the presence of an 
abnormal function of the endothelium that includes shear stress and the 
loss of NO bioactivity, causing vascular remodeling and dysfunction 
[14]. Given the fact that CNP secretion is increased in response to 
shear stress and that it triggers anti-remodeling effects on endothelial 
cells and vascular smooth muscle, it is possible that endothelial CNP 
produced a protective effect against arterial hypertension associated 
vascular dysfunctions, which could lead to consider the possible use 
of this peptide as pharmacological therapy [11]. Additional studies 
showed that a significant increase in CNP plasma level is related 
to hypertension in patients requiring coronary angiography [11]. 
It has been proposed that CNP produces a chronic regulation of 
blood pressure through different mechanisms such as suppression 
of vasopressin, ACTH, aldosterone synthesis and sympathetic tone. 
CNP could act as a protection agent for hypertension through NPR-B 
activation [11,14]. Results from different experimental models carried 
out by Costa et al. demonstrated that exogenous administration of 
CNP can reduce mean arterial pressure and increase nitric oxide 
synthase activity leading to an increased production of NO [34,35]. 
This mechanism could be mediated by the interaction of CNP with its 
receptor NPR-C [34,35]. Experiments performed on spontaneously 
hypertensive rats demonstrated that 14-days CNP infusion (0.75 
mg/h/rat, via subcutaneously implanted osmotic pumps) reduces 
systolic blood pressure in 15 mmHg compared with control group 
[36]. These findings suggest a possible use of CNP as a new strategy in 
anti-hypertensive therapy.
Cellular mechanisms that mediate CNP vasodilator effects 
include direct opening of K+ channel of the GIRK family, in smooth 
muscle vessels cells, and on the other hand, an indirect stimulation of 
NO release by vascular endothelium [9,34-36].
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Angiogenesis and revascularization
CNP derived from endothelium can activate endothelial cells 
promoting reparation of damaged blood vessels according to its pro-
angiogenic activity [11]. In damaged carotid arteries it was shown 
that systemic CNP infusion exalts endothelial growth and prevents 
intimal thickening [11]. Experimental studies showed that animals 
infused with CNP regenerate their endothelium during inflammatory 
events and cardiac tissue damage, as it occurs in acute myocarditis 
[37]. Treatment with CNP significantly improved cardiac function 
determined by an increase in maximum dP/dt and fractional 
shortening (%FS) and by a decrease in left ventricular end diastolic 
pressure [37]. This effect could be beneficial to prevent cardiac failure 
as well as myocardium injury induced by cardiac inflammatory 
processes [37].
Restenosis
As CNP inhibits vascular smooth muscle hyperplasia, it promotes 
endothelial cell proliferation, and it has anti-thrombotic and anti-
inflammatory actions, CNP appears to be an optimal candidate to be 
released from drug eluting stents [11]. Other beneficial action of CNP 
can be apply for coronary artery bypass surgery in patients requiring 
for auto-transplantation [11].
Atherosclerosis
Casco et al. demonstrated the presence of NPs in human 
atherosclerotic plaques, with an important increase in CNP levels 
and its receptor NPR-B, while Kuehnl et al. demonstrated that NPs 
are also markedly expressed in advanced atherosclerotic plaques of 
internal carotid arteries [38]. Although CNP and NPR-B expression 
were observed at endothelial cells and vascular smooth muscle cells, 
CNP secretion was also seen at atherosclerotic plaques associated 
macrophage cells, which seems to be an important source of the 
peptide in this pathologic structure [39].
Under physiological conditions, CNP secretion occurs at 
endothelial and vascular smooth muscle cells [11]. While growth 
of atherosclerotic plaque progresses the secretion pattern changes, 
showing less production in the previous mentioned cells and 
increased production in macrophages [11]. It is also important 
to know that there exists a suppression of CNP endothelial cells 
secretion causing by the oxidized form of LDL molecule found in 
the foam cells of atherosclerotic plaques [11]. In addition, it has been 
demonstrated that CNP inhibits oxidized LDL-stimulated vascular 
smooth muscle migration and proliferation, at least through a 
cGMP-dependent process, showing that CNP may play a role as a 
local antimigration factor during the process of intimal thickening in 
coronary atherosclerosis [40].
Pulmonary hypertension
In pulmonary hypertension, the bioactivity of NO is reduced and 
the same effect happens with prostacyclin and other endothelium-
dependent vasodilators, while production and secretion of 
endothelin-1 and other endogenous vasoconstrictors are increased 
[11]. Considering this scenario, exogenous CNP administration 
could have positive therapeutic effects for the treatment of pulmonary 
hypertension [11].
Postural orthostatic tachycardia syndrome
Clinical studies carried out by Li et al. [41] in children with 
postural orthostatic tachycardia syndrome (POTS) showed higher 
plasma C-type natriuretic peptide levels compared to control group 
(32.8±9.7 pg/mL vs 24.2±8.4 pg/mL; p<0.01). The samples were 
obtained from patients in supine position [41]. No differences were 
observed in plasma CNP levels obtained from POTS patients in upright 
and in supine position compared to control group [41]. Researchers 
suggest that CNP could be responsible for the vasodilation evidenced 
in children with POTS [41]. 
As metoprolol is an important drug for the treatment of POTS, 
Lin et al. [42] investigated the variation in CNP plasma levels with 
and without this drug in children and adolescent patients. In POTS 
patients without metoprolol, plasma CNP levels were higher than 
in control group (51.9±31.4 pg/ml vs. 25.1±19.1 pg/ml; p< 0.001) 
[42]. CNP plasma levels from metoprolol responder patients were 
significantly higher than non-responder one (59.1± 33.5 pg/ml 
vs. 34.8±16.7 pg/ml; p< 0.05) [42]. Investigators concluded that 
plasma CNP concentration could be used as a possible predictor of 
metoprolol therapeutic efficacy on POTS in children [42].
Vascular calcification
Huang et al. demonstrated that CNP inhibited calcification in 
rat vascular smooth muscle cells (VSMCs) through the cGMP/PKG 
pathway [43]. Also, clinical studies in human aortic valves showed 
that CNP is down-regulated in calcified human aortic valves [44]. 
Calcific aortic valve disease (CAVD) is characterized thickening 
of the valve leaflets, caused by fibrosis and calcification that lead to 
impairment of their motion [44]. In this sense, Yip et al. proved that 
CNP inhibited differentiation of valvular interstitial cells (VICs) to 
myofibroblasts and osteoblasts, phenotypes associated with CAVD 
[45]. Altogether, this evidence suggests a novel mechanism to 
explain the protective effect of CNP in the aortic valve and provide 
a new target for prophylaxis and therapy for cardiovascular diseases 
associated with ectopic calcification [43,45].
Myocardial aging
Evidence suggests that myocardial aging is a process characterized 
by LV fibrosis caused by a reduction in cardiomyocyte number, 
cardiac fibroblast proliferation, and collagen deposition, leading to 
ventricular dysfunction [46]. In this sense, it has been demonstrated 
that a decline in CNP bioavailability could be a contributor to age-
related LV fibrosis [46]. They demonstrated in a Fischer rat model 
of aging, that a progressive decline in circulating CNP characterizes 
natural aging and is strongly associated with a reciprocal increase in 
LV fibrosis [46]. By using adult human cardiac fibroblasts, they also 
demonstrated that the antiproliferative actions of high-dose CNP 
may involve a non-cGMP pathway via NPR-C [46]. These results 
open the possibility to develop a CNP-based therapy for myocardial 
aging as well as pathophysiological conditions with impaired LV 
function [46].
Conclusions
C-type natriuretic peptide is directly related to a variety of 
cardiovascular pathologies and processes. High levels of plasmatic 
and urinary CNP were found in patients suffering from heart failure, 
myocardial infarction and arterial hypertension, compared with 
healthy patients. It was also demonstrated by several researchers that 
CNP increases angiogenesis and revascularization. Different processes 
such as vascular smooth muscle hyperplasia inhibition, stimulation 
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of endothelial proliferation, anti-inflammatory and anti-thrombotic 
effects suggest that CNP could be considered as a pharmacological 
agent for vascular restenosis prevention to be used in patients with 
coronary surgery, and as a preventive agent for intima thickening in 
injury arterial vessels. Also, a modification in CNP secretion pattern 
was found in atherosclerotic plaques, changing from endothelial cells 
and smooth muscle cells that normally secreted it, to macrophages 
cells associated to those plaques. From a clinical diagnostic point 
of view, plasmatic and urinary levels are not yet established as a 
standard value to be implemented as a biomarker, and more studies 
are required in this field. Finally, and considering all the studies 
undergoing to the date, CNP research must keep moving forward 
to the study of cardiovascular pathologies from a patophysiological, 
pharmacological and diagnostically points of view.
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